Forxiga approved in Japan for type-1 diabetes
27 March 2019 07:00 GMT Forxiga approved in Japan for type-1 diabetes The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga(dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). Elisabeth Björk, Senior Vice President, Head of late Cardiovascular, Renal and Metabolism, R&D BioPharmaceuticals, said: "This approval of Forxiga in Japan means that people with type-1 diabetes whose glucose levels are not adequately controlled with insulin alone now have a new oral treatment option available to them. Forxiga will help